Katharina Marth

Hietzing, Austria

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications

Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort.

Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort.

Journal: Frontiers in allergy
Published: April 07, 2026

An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu® in Austrian Patients with Persistent Allergic Rhinitis.

An Observational Study to Determine the Real-Life Effectiveness of MP-AzeFlu® in Austrian Patients with Persistent Allergic Rhinitis.

Journal: Drugs - real world outcomes
Published: December 07, 2023

Combined analysis of five non-interventional studies of the effectiveness, tolerability, and safety of the extrafine fixed dose beclomethasone/formoterol combination in the treatment of asthma in Austria.

Combined analysis of five non-interventional studies of the effectiveness, tolerability, and safety of the extrafine fixed dose beclomethasone/formoterol combination in the treatment of asthma in Austria.

Journal: Respiratory medicine
Published: October 13, 2022

Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics.

Dupilumab rapidly improves asthma control in predominantly anti-IL5/IL5R pretreated Austrian real-life severe asthmatics.

Journal: Immunity, inflammation and disease
Published: February 24, 2021

TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.

TRICOP - A Real-world effectiveness study with a single-inhaler extrafine triple therapy over 52 weeks in Austrian patients with COPD.

Journal: Respiratory medicine
Published: November 11, 2020

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth.

COVID-19 in two severe asthmatics receiving benralizumab: busting the eosinophilia myth.

Journal: ERJ open research
Published: July 01, 2020

COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study.

COVID-19 in a severe eosinophilic asthmatic receiving benralizumab - a case study.

Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: June 11, 2020

Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.

Effectiveness of mepolizumab therapy in patients with severe eosinophilic asthma: Austrian real-life data.

Journal: Pulmonary pharmacology & therapeutics
Published: May 05, 2020

Benralizumab rapidly improves asthma control in Austrian real-life severe eosinophilic asthmatics.

Benralizumab rapidly improves asthma control in Austrian real-life severe eosinophilic asthmatics.

Journal: Allergy
Published: March 06, 2020

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands.

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands.

Journal: Pulmonary pharmacology & therapeutics
Published: June 19, 2019

Reslizumab in an invasively ventilated patient with acute respiratory failure.

Reslizumab in an invasively ventilated patient with acute respiratory failure.

Journal: The journal of allergy and clinical immunology. In practice
Published: March 20, 2019

Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.

Isolation of a high-affinity Bet v 1-specific IgG-derived ScFv from a subject vaccinated with hypoallergenic Bet v 1 fragments.

Journal: Allergy
Published: December 22, 2017
Showing 1-12 of 27

Last Updated: 09/26/2026